Harvest Fund Management Co. Ltd Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Harvest Fund Management Co. Ltd boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 45.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,707 shares of the company’s stock after purchasing an additional 5,544 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Moderna were worth $1,183,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of MRNA. Commerzbank Aktiengesellschaft FI boosted its stake in shares of Moderna by 1.7% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after acquiring an additional 93 shares during the last quarter. CVA Family Office LLC raised its holdings in Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after purchasing an additional 96 shares during the period. Claro Advisors LLC lifted its position in Moderna by 2.0% during the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after purchasing an additional 108 shares in the last quarter. McAdam LLC grew its holdings in Moderna by 1.1% during the second quarter. McAdam LLC now owns 11,075 shares of the company’s stock valued at $1,315,000 after purchasing an additional 117 shares during the period. Finally, 180 Wealth Advisors LLC increased its position in Moderna by 1.1% in the second quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after buying an additional 160 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 2,930 shares of company stock worth $217,170. Insiders own 15.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MRNA. Piper Sandler reaffirmed an “overweight” rating and set a $69.00 price objective (down from $115.00) on shares of Moderna in a research report on Monday, November 18th. Sanford C. Bernstein assumed coverage on shares of Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target for the company. Jefferies Financial Group reduced their price objective on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Finally, The Goldman Sachs Group dropped their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a report on Monday, September 16th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $84.00.

Moderna Trading Up 6.2 %

Moderna stock opened at $43.66 on Tuesday. The stock has a market cap of $16.80 billion, a P/E ratio of -7.50 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47. The firm’s 50 day moving average price is $54.96 and its 200-day moving average price is $93.71.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the previous year, the business posted ($1.39) earnings per share. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. On average, equities analysts predict that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.